BioMarin Pharmaceutical I... (BMRN)
NASDAQ: BMRN
· Real-Time Price · USD
58.02
-0.28 (-0.48%)
At close: Aug 14, 2025, 3:59 PM
58.20
0.31%
Pre-market: Aug 15, 2025, 08:52 AM EDT
BioMarin Pharmaceutical Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 657.24M | 338.2M | 426.86M | 322.29M | 256.59M | 205.46M | 167.65M | 147.02M | 99.99M | 71.61M | 141.56M | 83.91M | 54.07M | 39.35M | -64.08M | 15.92M | 837.21M | 795.09M |
Depreciation & Amortization | 83.25M | 91.14M | 96.43M | 99.68M | 106.36M | 105.31M | 104.39M | 102.08M | 101.19M | 101.05M | 101.97M | 103.4M | 105.44M | 107.4M | 108.04M | 109.41M | 109.21M | 107.19M |
Stock-Based Compensation | 181.58M | 181.96M | 202.51M | 204.51M | 209.41M | 211.65M | 207.1M | 198.98M | 205.25M | 202.17M | 196.31M | 193.47M | 187.83M | 195.59M | 197.26M | 200.96M | 202.1M | 192.22M |
Other Working Capital | 91.68B | 91.7B | 91.67B | 91.7B | -20.51M | -52.01M | -57.9M | -71.3M | -52.62M | 45.84M | 73.04M | 94.23M | 1.89B | 3.72B | 3.77B | 3.72B | 1.93B | 6.48M |
Other Non-Cash Items | -360.78M | 161.86M | 245.64M | 481.67M | 655.46M | 616.91M | 756.16M | 495.38M | 451.34M | 303.27M | -115.47M | -112.8M | -108.06M | -103.67M | 12.89M | 12.81M | 100.73M | 97.56M |
Deferred Income Tax | 116.33M | 84.24M | 56.1M | -11.13M | -38.34M | -38.34M | -44.98M | -71.48M | -60.65M | -63.25M | -52.09M | -4.33M | -13.36M | -14.14M | -15.61M | -46.73M | -881.84M | -896.17M |
Change in Working Capital | -1.31M | -68.23M | -83.15M | -97.12M | -229.5M | -225.28M | -336.54M | -252.57M | -200.96M | -176.33M | -96.38M | -83.36M | -106.88M | -78.93M | 66.03M | -12.4M | -98.29M | -81.81M |
Operating Cash Flow | 766.77M | 700.26M | 572.84M | 414.7M | 328.86M | 280.16M | 159.26M | 138.56M | 161.24M | 147.4M | 175.9M | 180.3M | 119.03M | 145.59M | 304.54M | 279.97M | 269.12M | 214.07M |
Capital Expenditures | -75.34M | -80.08M | -97.42M | -113.81M | -116.06M | -116.95M | -107.61M | -107.27M | -120.33M | -125.63M | -131.54M | -139.54M | -123.43M | -121.65M | -119.22M | -114.73M | -114.52M | -121.76M |
Cash Acquisitions | n/a | n/a | n/a | n/a | 24.06M | -27.05M | -21.49M | -21.49M | -51.45M | 2.2M | -3.35M | 12.27M | 16.54M | 17.65M | 20.39M | -4.06M | -6.02M | -17M |
Purchase of Investments | -417.22M | -377.86M | -410.25M | -493.82M | -619.91M | -769.8M | -868.5M | -881.47M | -751.05M | -684.81M | -611.81M | -657.38M | -757.38M | -847.33M | -937.14M | -896.87M | -692.55M | -735.44M |
Sales Maturities Of Investments | 511.11M | 579.29M | 633.02M | 591.62M | 691.45M | 781.28M | 864.86M | 894.43M | 799.46M | 679.29M | 620M | 666.18M | 653.71M | 652.23M | 691.05M | 712.72M | 734.66M | 655.77M |
Other Investing Acitivies | -2.61M | 109.47M | 119.47M | 120.23M | 97.74M | 37.05M | 21.49M | 14.82M | 44.78M | -8.88M | 106.68M | 97.73M | 93.37M | 91.36M | -21.39M | 3.07M | 5.11M | 16.61M |
Investing Cash Flow | 19.42M | 122.49M | 136.49M | -4.88M | -34.52M | -95.47M | -111.24M | -100.99M | -78.59M | -137.82M | -20.03M | -20.74M | -117.19M | -207.74M | -366.31M | -299.87M | -73.32M | -201.81M |
Debt Repayment | -494.93M | -494.94M | -494.99M | -495.03M | -711K | -1.31M | -2.29M | -3.21M | -3.12M | -3.05M | -2.6M | -2.18M | -2.22M | -2.52M | -3.04M | -378.32M | -381.83M | 203.7M |
Common Stock Repurchased | -4.91M | -21.7M | -71.65M | -70.66M | -75.2M | -74.84M | -76.32M | -75.99M | -77.77M | -72.76M | -54.28M | -52.07M | -51.45M | -49.66M | -45.8M | -46.4M | -46.72M | -37.09M |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -44.72M | -27.49M | -31.46M | -28.23M | -19.42M | -19.46M | -16.44M | -15.49M | -7.25M | -31.06M | -16.05M | -12.94M | -21.48M | 1.56M | 2.99M | -2.28M | 5.52M | -14.09M |
Financial Cash Flow | -539.65M | -522.43M | -526.45M | -518.47M | -20.13M | -20.78M | -18.73M | -18.7M | -10.37M | -34.11M | -18.65M | -15.12M | -23.7M | -964K | -48K | -380.6M | -376.31M | 176.43M |
Net Cash Flow | 76.65M | 301.81M | 187.72M | -109.97M | 277.77M | 166.92M | 30.6M | 23.9M | 74.58M | -25.37M | 137.25M | 144.37M | -21.73M | -61.87M | -61.88M | -398.53M | -177.37M | 190.68M |
Free Cash Flow | 691.43M | 620.18M | 475.42M | 300.88M | 212.8M | 163.21M | 51.65M | 31.29M | 40.91M | 21.77M | 44.36M | 40.76M | -4.39M | 23.95M | 185.31M | 165.24M | 154.59M | 92.31M |